skinny.

Latest / GK Daily Podcast

GK Daily Special Edition: The Moderna Cancer Vaccine — mRNA's Second Act

Moderna stock closed up 83% on August 19, 2026 — and it had nothing to do with COVID. This breaking-news special edition covers the Phase 3 results for V940 (mRNA-4157) plus Keytruda in more than 1,100 resected high-risk melanoma patients: the trial hit its primary endpoint on recurrence-free survival and its key secondary endpoint on distant metastasis, with FDA approval possible in late 2026 or 2027. Plus the same-day approval of mFLUSIVA, Moderna's mRNA flu vaccine and fourth US product. We walk through how a personalized neoantigen vaccine is actually built — biopsy, tumor sequencing, up…

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.